Intensity TherapeuticsINTS
Market Cap: $56.2M
About: Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
28% more funds holding
Funds holding: 18 [Q1] → 23 (+5) [Q2]
0.34% more ownership
Funds ownership: 11.91% [Q1] → 12.25% (+0.34%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
3% less capital invested
Capital invested by funds: $8.49M [Q1] → $8.23M (-$260K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Benchmark Robert Wasserman 55% 1-year accuracy 24 / 44 met price target | 194%upside $12 | Speculative Buy Reiterated | 11 Jul 2024 |